To provide a biological interpretation for clinical observations as well as a future direction for larger trials, we performed a drug target validation to examine whether genetic variation of HMG-CoA reductase (HMGCR) is associated with the risk to develop ankylosing spondylitis. Here, HMGCR is linked to ankylosing spondylitis.